📰 Cassava Sciences News
Page 20 - Cassava Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cassava Sciences. Real-time updates on events, politics, business and more.
June 1, 2023
AUSTIN, Texas, June 01, 2023 -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present... | June 1, 2023
May 16, 2023
The psychosis in Parkinson's and Alzheimer's disease market size shall grow during the forecast period (2023-2032). This increase will be due to rising disease awareness and improving diagnosis
May 16, 2023
/PRNewswire/ -- DelveInsights Psychosis in Parkinsons and Alzheimers Disease Market Insights report includes a comprehensive understanding of current...
May 14, 2023
If broadly covered, Leqembi, the new Alzheimer's drug from Biogen (BIIB) and Eisai (ESALF) (ESAIY), could add $2B - $5B costs to Medicare annually. Read more here.
May 13, 2023
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) – Equities researchers at HC Wainwright issued their Q2 2023 EPS estimates for shares of Cassava Sciences in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.58) per share for the quarter. HC […]
May 12, 2023
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.
May 12, 2023
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) – Investment analysts at HC Wainwright increased their FY2023 EPS estimates for shares of Cassava Sciences in a report issued on Tuesday, May 9th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn $0.84 per share for the year, up from their previous forecast of […]
May 12, 2023
In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report). Th...
May 11, 2023
The Cognition Maintenance Study is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition... | May 11, 2023
May 11, 2023
11.05.2023 - The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition Scores.Top-line Clinical Results of the CMS Are ... Seite 1